Early ‘top-down’ therapy reduces Crohn’s disease complications
-
May 15
PROFILE follow-up data showed lower rates of surgery, hospitalization, and disease progression versus step-up treatment.
Browse By
Biliary Tract
Colon
Esophagus
Liver
Pancreas
Small Bowel
Stomach
The GI hospitalist: A practice-changing health care opportunity
-
April 23
-
by Vasili Kalas, MD, PhD
The model is reshaping inpatient care, despite slow national adoption.
Pancreatic cystic lesions: A case-based approach
-
April 17
-
by Ross C.D. Buerlein, MD , Himesh B. Zaver, MD , Vanessa M. Shami, MD
Dr. Vanessa Shami, along with Drs. Ross Buerlein and Himesh Zaver, review pancreatic cysts in a case-based approach.
Navigating primary sclerosing cholangitis: Diagnosis and the 5 pillars of management
-
February 1
-
by Judy A. Trieu, MD, MPH, Mahesh Krishna, MD, David N. Assis, MD
Primary sclerosing cholangitis remains a challenging disease to diagnose and manage, due to varying presentations, associated disease processes, and lack of targeted treatment.
The Latest
Risk of colorectal cancer and mortality in older adults by adenoma history
-
by Julia Cipriano
Findings “raise major questions” about how clinically relevant surveillance colonoscopy remains in older adults with prior adenomas.
Early ‘top-down’ therapy reduces Crohn’s disease complications
-
by Alun Evans
PROFILE follow-up data showed lower rates of surgery, hospitalization, and disease progression versus step-up treatment.
Study supports sex- and comorbidity-based cutoffs for stopping Barrett's surveillance
-
by Alun Evans
“Most physicians make future surveillance decisions heavily based on perceived risk for EAC without considering … life expectancy.”
Thiopurines can be safely stopped when switching to subcutaneous infliximab, trial finds
-
by Olivia Anderson
MINIMISE trial found no rise in antidrug antibodies or disease activity at 24 weeks after withdrawal.
Switching to subcutaneous infliximab may cut treatment failure in IBD
-
by Bob Alaburda
Randomized trial finds 48-week treatment failure dropped from 40% to 15% after switching from IV.
